Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine in Parkinson's disease
NCT07093944Phase 2Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Apr 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetylcysteine in Parkinson's disease (PD) (2 arms), sponsored by Kurdistan University of Medical Sciences. Primary endpoints: Single-photon emission computerized tomography brain imaging at 1 year and Unified Parkinson's Disease Rating Scale at 1 year. Started Apr 2018; status: completed.
02
Drugs
acetylcysteine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07093944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093944.